Oxford, England-based Optellum designed the Virtual Nodule Clinic as a clinical decision-support tool for helping clinicians identify and track at-risk patients who present suspicious lung nodules that may or may not be cancerous. The platform received FDA 510(k) clearance in March 2021.
Since receiving FDA clearance, Optellum has received support through partnerships with the National Health Service (NHS) with funding from Innovate UK and the National Institute for Health Research (NIHR), culminating in the European approval, according to a news release.
The Virtual Nodule Clinic integrates the clinically validated Lung Cancer Prediction (LCP) score based on imaging AI. Optellum said it has the potential to improve clinical care coordination and decisions with the intention of getting patients treated before…